TKTL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, increased levels of TKTL1 have been reported in response to decitabine (DAC) treatment in primary acute myeloid leukemia (AML) samples [16] and correlated to the acquisition of tyrosine kinase inhibitor resistance in chronic myeloid leukemia (CML) [17].